US · BYSI
BeyondSpring Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Florham Park, NY 10005
- Website
- beyondspringpharma.com
Price · as of 2024-12-31
$1.49
Market cap 55.52M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $19.25 | ||||
| 2017 | $28.00 | ||||
| 2018 | $18.06 | ||||
| 2019 | $13.64 | ||||
| 2020 | $12.82 | ||||
| 2021 | $1.86 | $82.45 | $0.00 | $0.00 | $0.00 |
| 2022 | $1.43 | $27.60 | $0.00 | $0.00 | $0.00 |
| 2023 | $2.91 | $37.60 | |||
| 2024 | $1.67 |
AI valuation
Our deep-learning model estimates BeyondSpring Inc.'s (BYSI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.49
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BYSI | BeyondSpring Inc. | $1.49 | 55.52M | — | — | — | — | -5.97 | -2.02 | — | -7.56 | — | -2.02 | 0.00% | — | — | 37.26% | 22.88% | -37.63% | -0.02 | — | 2.60 | 0.27 | 0.28 | -4815.00% | — | 56.00% | -25.12% | -1.49 | 43.56% | 0.00% | 0.00% | 0.00% | -7.31 | -3.84 | — | -16.03 |
| ALXO | ALX Oncology Holdings Inc… | $2.11 | 114.42M | — | — | — | — | -0.41 | 0.49 | — | 0.42 | — | 0.49 | 0.00% | — | — | -88.91% | -1054.84% | -69.10% | 0.15 | -82.40 | 7.26 | 6.95 | 0.00 | -3102.00% | — | -705.00% | -221.24% | -6.59 | -905.96% | 0.00% | 0.00% | 0.00% | 0.39 | 0.45 | — | -7.15 |
| ATYR | aTyr Pharma, Inc. | $0.96 | 94.05M | +2,378% | +42% | — | +2,039% | -3.94 | 3.61 | 1074.42 | -2.92 | — | 3.61 | 100.00% | -28899.57% | -27243.83% | -79.69% | -723.88% | -58.88% | 0.19 | — | 5.48 | 4.93 | -0.03 | -851.00% | -3343.00% | 8481.00% | -27.40% | -4.62 | -737.41% | 0.00% | 0.00% | 0.00% | -2.85 | -2.80 | 824.03 | -3.56 |
| BMEA | Biomea Fusion, Inc. | $1.37 | 81.51M | — | — | — | — | -0.71 | 1.90 | — | -0.34 | -6.23 | 1.90 | 0.00% | — | — | -125.38% | -6089.18% | -98.92% | 0.17 | — | 3.15 | 2.69 | 0.35 | 1134.00% | — | 2030.00% | -122.90% | -5.53 | -5082.67% | 0.00% | 0.00% | 0.00% | -0.34 | -0.40 | — | -9.96 |
| CAMP | CAMP4 Therapeutics Corpor… | $4.49 | 95.37M | — | -59% | — | — | -1.58 | 1.29 | 125.35 | -0.51 | -0.81 | 1.29 | 100.00% | -8142.33% | -7943.40% | 719.97% | 75.53% | -57.27% | 0.14 | — | 6.92 | 6.68 | 1.08 | 19556.00% | — | 807.00% | -56.29% | -4.75 | 65.45% | 0.00% | 0.00% | 0.00% | -0.50 | -0.57 | 40.39 | -1.91 |
| DTIL | Precision BioSciences, In… | $4.20 | 55.67M | +1,686% | -46% | +221% | +1,082% | 4.94 | 0.63 | 0.52 | -1.54 | — | 0.63 | 100.00% | -38.08% | 10.43% | 19.05% | 78.77% | 4.84% | 0.53 | -14.68 | 6.34 | 5.88 | -4.13 | -10652.00% | 4098.00% | -3206.00% | -165.83% | -3.90 | 176.73% | 0.00% | 0.00% | 0.00% | 0.80 | 0.36 | -0.30 | -4.11 |
| GUTS | Fractyl Health, Inc. Comm… | $0.47 | 33.88M | +4,277% | +19% | — | +4,370% | -0.89 | 2.16 | 660.15 | -0.61 | — | 2.16 | 46.24% | -100570.97% | -73864.52% | 46.32% | -484.68% | -74.55% | 2.20 | — | 3.63 | 3.41 | 0.05 | -1818.00% | -2250.00% | 5582.00% | -109.60% | -3.31 | -348.68% | 0.00% | 0.00% | 562.21% | -0.60 | -0.84 | 606.77 | -7.20 |
| HYFT | MindWalk Holdings Corp. | $1.13 | 52.76M | +1,308% | +315% | — | — | -2.28 | 2.92 | 2.84 | -2.48 | — | 4.82 | 47.31% | -50.47% | -123.30% | -105.08% | -30.71% | -57.90% | 0.57 | -1237.63 | 2.08 | 1.72 | -0.09 | -1262.00% | -203.00% | 2775.00% | -10.44% | -0.71 | -20.45% | 0.00% | 0.00% | 10.84% | -5.85 | -9.96 | 2.95 | -2.17 |
| QNCX | Quince Therapeutics, Inc. | $0.13 | 7M | — | — | — | — | -1.15 | 2.17 | — | -1.09 | -2.05 | -2.18 | 0.00% | — | — | -98.63% | -409.00% | -38.57% | 0.49 | — | 6.05 | 5.72 | -0.24 | 5595.00% | — | 7430.00% | -49.23% | -4.38 | -229.62% | 0.00% | 0.00% | 0.00% | -0.69 | -1.22 | — | -5.41 |
| RPTX | Repare Therapeutics Inc. | $2.65 | 114.24M | +786% | -68% | — | — | -0.59 | 0.33 | 0.94 | 1.12 | — | 0.33 | 74.98% | -174.88% | -158.37% | -46.63% | 2379.11% | -39.35% | 0.01 | — | 6.77 | 6.53 | 0.92 | -1031.00% | 458.00% | -4078.00% | -152.11% | -3.02 | 1944.67% | 0.00% | 0.00% | 0.00% | 1.08 | 1.32 | -1.88 | -2.58 |
| UNCY | Unicycive Therapeutics, I… | $6.93 | 148.94M | +172% | — | — | — | -1.03 | 5.08 | — | -0.34 | -0.30 | 5.08 | 0.00% | — | — | -2028.11% | 209.66% | -160.18% | 0.10 | -452.35 | 1.28 | 1.08 | 0.70 | 33750.00% | -10000.00% | 5658.00% | -75.83% | -1.18 | 187.01% | 2.90% | -3.00% | 46.52% | -0.39 | -0.43 | — | -6.63 |
About BeyondSpring Inc.
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
- CEO
- Lan Huang
- Employees
- 40
- Beta
- 0.53
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.49) − 1 = — (DCF, example).